Using inhaled ginger and lemon aromatherapy to reduce nausea and vomiting in cancer patients
Official title: Efficacy of Ginger and Lemon Essential Oil Inhalation on Chemotherapy-induced Nausea and Vomiting in Patients with Haematological Malignancies: a Multicenter, Double-blind, Randomised Controlled Trial
Run by University Hospital, Limoges · NCT06150469 · Data updated 2026-11-12
This study is testing if breathing in a mix of ginger and lemon scents can help cancer patients feel less nauseous and vomit less during chemotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 286 (estimated) |
| Sponsor | University Hospital, Limoges Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Brivé and 3 other locations) |
| Status | Recruiting |
| Started | April 17, 2024 |
| Main results expected | December 16, 2025 |
| Study ends | December 16, 2026 |
| Registry record updated | December 12, 2024 |
| Trial ID | NCT06150469 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with hematological malignancies who are starting chemotherapy and can use the aromastick.
✕Probably not a fit
Patients with asthma, allergies to essential oils, or those who have previously received aromatherapy for nausea may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to evaluate the effectiveness of inhaling a blend of ginger and lemon essential oils compared to a placebo in managing chemotherapy-induced nausea and vomiting in patients with hematological malignancies. The study will be conducted across multiple centers, focusing on improving patients' nausea and vomiting scores, quality of life, and appetite. A team of trained healthcare professionals will oversee the administration of the aromatherapy, ensuring a safe and scientifically sound approach. The study is designed to meet the needs of patients seeking supportive care during their treatment.
Why it matters
Potential benefit: If successful, this approach could significantly improve the management of nausea and vomiting for patients undergoing chemotherapy.
How similar studies have gone: While the use of aromatherapy in cancer care is gaining interest, this specific approach using ginger and lemon essential oils is relatively novel and has not been extensively tested in similar studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged over 18 years, * Chemo-naive patients at inclusion, * Patients with haematological malignancies treated treated with chemotherapy, * Patients physically and mentally able to use the aromastick, * Patients who speak, read and write French, * Patients who have given signed consent, * Patients with social security cover. Exclusion Criteria: * Asthmatic patients. * Patients with anosmia. * Patients allergic to EO, lemon or ginger. * Patients who have already received aromatherapy to treat chemotherapy-induced nausea and vomiting, * Patients practising herbal medicine or acupuncture, * Pregnant and breast-feeding women, * Patients under guardianship, tutorship or curatorship, * Patients taking part in interventional studies involving antiemetic drugs or nutritional products, * Patients who have already had cancer.
Where it's running
-
Ch Brive
Brivé, France Recruiting -
Chu La Reunion
La Réunion, France Recruiting -
University Hospital, Limoges
Limoges, France Recruiting -
Ch Poissy
Saint-Germain-en-Laye, France Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lower Dose Cyclophosphamide After Haploidentical Stem Cell Transplant
This trial tests whether giving half the usual amount of cyclophosphamide after haploidentical stem cell transplantation can still prevent GVHD in adults with blood cancers.
-
Chlorophyllin to reduce mouth sores before allogeneic stem cell transplant
This phase II study tests whether taking chlorophyllin by mouth can lower the chances and severity of mouth ulcers in patients aged 12–65 undergoing radiation-based conditioning before a first allogeneic stem cell transplant.
-
First-in-human test of DS3790a for hematological malignancies
This first-in-human trial will test DS3790a alone and with other drugs to see if it's safe, how it behaves in the body, and whether it helps adults with hematological malignancies.
-
18F‑Pentixafor PET imaging for blood cancers
This will test whether 18F‑Pentixafor PET scans help diagnose, stage, and check treatment response in adults with suspected or confirmed hematologic malignancies.
-
Improving GVHD prevention after donor stem cell transplant
This study will test whether a lower dose versus the standard dose of post-transplant cyclophosphamide, given with sirolimus and MMF, improves quality of life for people aged 60 and older having a reduced-intensity allogeneic stem cell transplant.
-
Long-term follow-up for patients treated with Galapagos CAR T-cell therapies
This study is checking how well Galapagos CAR T-cell therapies work and their safety for patients over 15 years after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.